TABLE 3.

Comparative antibacterial effects of free-drug serum concentrations of simulations of telavancin, teicoplanin, and vancomycin against pooled data from 4 MRSA strains

ABE measureValue
TelavancinTeicoplaninVancomycin
No. of simulations181217
Log change in viable count (log CFU/ml) at (h):
    6−3.5 ± 0.6a−2.0 ± 0.4−2.5 ± 0.7
    12−3.5 ± 0.5a−2.7 ± 0.2−3.0 ± 0.7
    24−3.0 ± 0.8−2.8 ± 0.5−2.8 ± 0.8
    36−3.0 ± 0.7−2.7 ± 0.8−2.7 ± 0.9
    48−2.8 ± 0.8−2.1 ± 1.4−2.8 ± 1.0
Maximum reduction in viable count (log CFU/ml)−4.0 ± 0.5a−3.2 ± 0.5−3.3 ± 0.6
AUBKC24 (log CFU/ml·h)21.7 ± 7.7a42.0 ± 5.336.9 ± 13.7
AUBKC48 (log CFU/ml·h)43.8 ± 20.0a76.3 ± 21.165.9 ± 29.4
  • a Telavancin was superior to vancomycin and teicoplanin (P < 0.05).